Pregnancy Risks With First Trimester GLP-1 Continuation - Summary - MDSpire
Advertisement
Pregnancy Risks With First Trimester GLP-1 Continuation
Claims-based target trial emulation found no clear association between continued GLP-1 receptor agonist use in early pregnancy and nonlive birth, fetal growth abnormalities, or major congenital malformations.
To evaluate the association of GLP-1 receptor agonist continuation during the first trimester of pregnancy with nonlive birth, abnormal fetal growth, and congenital malformations.
Key Findings:
Estimated 30% risk of nonlive birth among patients who continued treatment compared to 27% among those who did not; adjusted risk ratio of 1.09 suggests no significant difference in risk.
No clear increase in fetal growth abnormalities or major congenital malformations was identified; major congenital malformations occurred in about 8% of infants exposed to continued treatment and 7% in the noncontinuation group.
Elective termination was more frequent among patients who continued treatment.
Interpretation:
The findings suggest no strong association between first-trimester GLP-1 receptor agonist continuation and adverse pregnancy outcomes, though uncertainty remains for less common outcomes.
Limitations:
Observational design may leave residual confounding, particularly related to glycemic control.
Most patients classified as continuers received only one additional prescription, limiting assessment of prolonged exposure.
Study could not evaluate pregnancy losses prior to clinical recognition.
Estimates for major congenital malformations and small for gestational age were imprecise due to small event numbers.
Conclusion:
The study suggests no strong effect of GLP-1 receptor agonist continuation into the first trimester on adverse pregnancy outcomes, which is important for clinical decision-making.
Pregnant patients who sat less and moved more at light intensity had a lower risk of adverse outcomes in a prospective cohort study, but the findings do not prove causation.
Three amino acid metabolism genes showed diagnostic signal in testicular tissue, though small sample sizes and computational methods limit clinical translation.
